annb0t
Top 20
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment
Secondary and topline exploratory endpoints trended favorably for sparsentan
Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment
Sparsentan was well-tolerated with a consistent safety profile across all clinical trials conducted to date and comparable to irbesartan
ST. GALLEN, Switzerland, May 2, 2023 /CNW/ -- CSL Vifor today ann...
>>> Read more: Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Secondary and topline exploratory endpoints trended favorably for sparsentan
Treatment with sparsentan resulted in a reduction of proteinuria that was sustained through 108 weeks of treatment
Sparsentan was well-tolerated with a consistent safety profile across all clinical trials conducted to date and comparable to irbesartan
ST. GALLEN, Switzerland, May 2, 2023 /CNW/ -- CSL Vifor today ann...
>>> Read more: Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
